This study evaluated the anti-adipogenic effects and mechanisms underlying the action of Lactobacillus fermentum MG4231 and MG4244 strains on adipogenesis and lipid accumulation in 3T3-L1 preadipocytes. Treatment with cell-free extracts (CFEs) from the two strains reduced lipid accumulation and intracellular triglyceride production in 3T3-L1 adipocytes by more than 50%. The inhibitory effects of L. fermentum on lipid accumulation were mediated by the downregulation of FAS and aP2 resulting from the inhibition of PPARγ and C/EBPα gene expression. Moreover, AMPK and HSL phosphorylation was upregulated by CFE treatment. These results indicated that the anti-adipogenic and lipolysis activities of L. fermentum strains were caused by increased AMPK and HSL phosphorylation. Both strains displayed high leucine arylamidase and β-galactosidase enzymatic activity, with excellent adhesion to epithelial cells. Therefore, we identified L. fermentum as potential new probiotics for the prevention of obesity.

本研究评估了发酵乳杆菌MG4231 和 MG4244 菌株对 3T3-L1 前脂肪细胞脂肪生成和脂质积累作用的抗脂肪生成作用和机制。用来自两种菌株的无细胞提取物 (CFE) 处理使 3T3-L1 脂肪细胞中的脂质积累和细胞内甘油三酯的产生减少了 50% 以上。的抑制作用发酵乳杆菌上脂质蓄积是由FAS的和AP2从PPARγ和C /EBPα基因表达的抑制导致的下调来介导。此外，CFE 处理可上调 AMPK 和 HSL 磷酸化。这些结果表明发酵乳杆菌的抗脂肪生成和脂肪分解活性菌株是由增加的 AMPK 和 HSL 磷酸化引起的。两种菌株均显示出高亮氨酸芳基酰胺酶和 β-半乳糖苷酶酶活性，对上皮细胞具有极好的粘附性。因此，我们将发酵乳杆菌确定为预防肥胖的潜在新型益生菌。